Replies to post #303683 on Avid Bioservices Inc (CDMO)

[biopharm]

Has everyone looked into all Peregrine ties with ex Peregrine employee Janet Nuttall, relation Aidan Nuttall (ex Maxim, Chiltern, Abingdon Life Sciences that had dealings with Stason!...now working with Diana Wood and Janet Nuttall at KC Specialty Therapeutics in St Louis Missouri....

How many times has Peregrine been sabotaged? Would Stason just be another one of those times where Peregrine was promised something and things were pulled back? Is it odd that Aidan Nuttall was with Abingdon Life Sciences that also made strategic dealings with Stason, possibly as an incentive of some sort ?? ...and when I seen Janet Nuttall ex Peregrine was she approached before or after she was with Peregrine.....there are many questions to ask.....

Well so much more but Diana Wood had me searching for how she played into KC Specialty in Missouri (same location that KCM just bought big into Peregrine ..)

Remember though Diana and Aidan and Chen Long-shiuh recently with some patents re: CK9 but Stason as majority owner??? Three private investors ??? Has any PS Targeting data been used to move forward in other areas ....has Peregrine been a long time target ??? I say yes

http://stks.freshpatents.com/Ck9-Llc-inventors-nm2.php

In 2011 CK9 LLC, was established to develop New Chemical Entities (NCEs) for the veterinary market. The initial product is a new drug to treat Chronic Pancreatitis in canines. CK9 LLC was formed by a group of angel investors including Stason Pharmaceuticals (majority owner), and three private investors. Together they raised $500,000 to fund a pilot study at Texas A&M School of Veterinary Sciences in 2012.

Our Team:

Diana Wood (CEO)

Aidan Nuttall (Executive VP)

Lyndsy Hassett (Director BD, Stason Pharmaceuticals)

Dr. Jorg Steiner (Med.vet., Dr.med.vet, PhD, DACVIM, DECVIM-CA, AGAF, Texas A&M University GI Lab, and Veterinary consultant & POC study director):
...
...

CK9 REGULATORY MILESTONES:

• INAD request (012-528) filed June 13, 2014.
• Non-provisional Patent (62/005,070) filed May 2015
• PCT application filed (PCT/US15/33237) June 2015
• CVM Annual Sponsor Fees waived in 2014, 2015, and 2016.
• Pre-Development meeting with FDA (CVM) in February 2015.
• Pivotal Field efficacy Protocol & Quality of Life tool completed and under review at FDA
• Minor Use Minor Species (MUMS) application filed with OMUMS
...
...
http://ck9llc.com/about-2/

________ Diana Wood 1st at Maxim Pharmaceuticals with Aidan Nuttall

Maxim Pharmaceuticals, Inc., San Diego, appointed L. Edward Kirk to the new position of senior director of clinical and regulatory affairs. He will manage the company's phase III clinical trial of Maxamine™ for the treatment of malignant melanoma Kirk had been a senior product manager for PPD Pharmaco, Inc., a contract research organization.

The company also appointed several others to help develop and commercialize Maxamine. They are Richard A. Angelo, Ph.D. , who will direct clinical affairs; Diana Wood , who will direct marketing and business development; and Kenneth S. Ross , who will manage clinical and regulatory compliance.


https://academic.oup.com/jnci/article/89/6/419/2526936/Awards-Appointments-Announcements

____________... also Chiltern with Aidan!

Chiltern International, the largest privately held global Clinical Research Organization, is continuing its US expansion with the announcement that Diana Wood has been promoted to Vice President of Business Development for the United States.

Diana joined Chiltern at the beginning of 2003 in the Business Development Department and has achieved significant success with several key new business wins. In her new role she will have responsibility for business development in the United States marketplace from Chiltern's three US offices in Carlsbad, CA, Atlanta, GA and Austin, TX.

Before joining Chiltern Diana worked in Clinical Development with a focus in Oncology and Medical Devices plus in biotechnology Business Development.

Dr Aidan Nuttall, President Chiltern US, commented “We are very happy with the progress made in Business Development in the last year and with Diana’s appointment, Chiltern US is poised to move ahead rapidly taking significant market share in the coming year.

"Even though the industry has traditionally continued to spend on R&D, even in lean economic times, the recent growth figures and lower interest rates do seem to be signaling a reasonable economic recovery and we want to be in the best position possible to make the most of that.

"The introduction of a senior management team is the next step to support the company’s continued growth here and to achieve its long term strategic goals worldwide.”

Established in London in 1982, clinical research organization Chiltern International provides clinical operations, project management, data management, biostatistics, medical writing, quality assurance and regulatory and medical affairs services to the pharmaceutical, biotechnology and medical device industries. The company also offers clinical contract personnel services to pharmaceutical and biotechnology clients. It has ten international offices – three in the United States and seven in Europe.

https://www.realwire.com/releases/chiltern-confirms-us-growth-with-vp-promotion

_____________________